Visualitza per autor "Gelderblom, Hans"
Ara mostrant els elements 1-5 d 5
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
Bauer, Sebastian; Heinrich, Michael C.; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (American Association for Cancer Research, 2021-12-01) -
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
Jones, Robin L.; Valverde Morales, Claudia Maria; Benson, Charlotte; Blay, Jean-Yves; Gelderblom, Hans; George, Suzanne (Springer Nature, 2020-04-14) -
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Gelderblom, Hans; Jones, Robin; Blay, Jean-Yves; George, Suzanne; von Mehren, Margaret ; Zalcberg, John; Serrano, Cesar (Elsevier, 2023-07-20) -
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Schöfski, Patrick; Heinrich, Michael C.; Bauer, Sebastian; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (BMC, 2022-12-13) -
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Schoffski, Patrick; Heinrich, Michael; Jones, Robin; George, Suzanne; Gelderblom, Hans; von Mehren, Margaret; Serrano, Cesar (Nature Portfolio, 2024-02)